COMPASS THERAPEUTICS INC.
NASDAQ: CMPX (Compass Therapeutics, Inc.)
Kemas kini terakhir: 5 jam lalu5.65
-0.13 (-2.25%)
| Penutupan Terdahulu | 5.78 |
| Buka | 5.73 |
| Jumlah Dagangan | 3,677,758 |
| Purata Dagangan (3B) | 2,125,421 |
| Modal Pasaran | 1,004,920,832 |
| Harga / Jualan (P/S) | 269.28 |
| Harga / Buku (P/B) | 5.33 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 2 Mar 2026 |
| Margin Operasi (TTM) | -7,273.06% |
| EPS Cair (TTM) | -0.400 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.79% |
| Nisbah Semasa (MRQ) | 8.33 |
| Aliran Tunai Operasi (OCF TTM) | -44.17 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -25.01 M |
| Pulangan Atas Aset (ROA TTM) | -26.41% |
| Pulangan Atas Ekuiti (ROE TTM) | -41.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Compass Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 14.16% |
| % Dimiliki oleh Institusi | 67.95% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tang Capital Management Llc | 31 Dec 2025 | 16,790,809 |
| Suvretta Capital Management, Llc | 31 Dec 2025 | 14,182,379 |
| Enavate Sciences Gp, Llc | 31 Dec 2025 | 7,788,150 |
| Blackstone Inc. | 31 Dec 2025 | 6,126,182 |
| Rock Springs Capital Management Lp | 31 Dec 2025 | 3,927,202 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 3,606,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (D. Boral Capital, 430.97%) | Beli |
| Median | 10.00 (76.99%) | |
| Rendah | 10.00 (Canaccord Genuity, 76.99%) | Beli |
| 10.00 (Citizens, 76.99%) | Beli | |
| Purata | 16.67 (195.04%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 5.16 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 06 Jan 2026 | 30.00 (430.97%) | Beli | 4.91 |
| Canaccord Genuity | 03 Dec 2025 | 10.00 (76.99%) | Beli | 5.28 |
| Citizens | 03 Dec 2025 | 10.00 (76.99%) | Beli | 5.28 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Jan 2026 | Pengumuman | Compass Therapeutics Provides Corporate Update |
| 05 Jan 2026 | Pengumuman | Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Jan 2026 | Pengumuman | Compass Therapeutics Announces Key Leadership Appointments |
| 17 Dec 2025 | Pengumuman | Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |